These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 20609549)

  • 1. Observational study of blue dye-assisted four-node sampling for axillary staging in early breast cancer.
    Narui K; Ishikawa T; Kito A; Shimizu D; Chishima T; Momiyama N; Ichikawa Y; Sasaki T; Nozawa A; Inayama Y; Shimada H; Endo I
    Eur J Surg Oncol; 2010 Aug; 36(8):731-6. PubMed ID: 20609549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blue-dye technique complements four-node sampling for early breast cancer.
    Ishikawa T; Momiyama N; Hamaguchi Y; Tanabe M; Tomita S; Ichikawa Y; Nakatani Y; Sasaki T; Nozawa A; Inayama Y; Inui K; Shimada H
    Eur J Surg Oncol; 2005 Dec; 31(10):1119-24. PubMed ID: 16005597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sentinel node biopsy versus low axillary sampling in women with clinically node negative operable breast cancer.
    Parmar V; Hawaldar R; Nair NS; Shet T; Vanmali V; Desai S; Gupta S; Rangrajan V; Mittra I; Badwe RA
    Breast; 2013 Dec; 22(6):1081-6. PubMed ID: 23948301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective feasibility study of sentinel node biopsy by modified Indigocarmine blue dye methods after neoadjuvant chemotherapy for breast cancer.
    Kida K; Ishikawa T; Yamada A; Shimizu D; Tanabe M; Sasaki T; Ichikawa Y; Endo I
    Eur J Surg Oncol; 2015 Apr; 41(4):566-70. PubMed ID: 25650249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sentinel lymph node as a new marker for therapeutic planning in breast cancer patients.
    Gipponi M; Bassetti C; Canavese G; Catturich A; Di Somma C; Vecchio C; Nicolò G; Schenone F; Tomei D; Cafiero F
    J Surg Oncol; 2004 Mar; 85(3):102-11. PubMed ID: 14991881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The predictive value of methylene blue dye as a single technique in breast cancer sentinel node biopsy: a study from Dharmais Cancer Hospital.
    Brahma B; Putri RI; Karsono R; Andinata B; Gautama W; Sari L; Haryono SJ
    World J Surg Oncol; 2017 Feb; 15(1):41. PubMed ID: 28173818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blue dye versus combined blue dye-radioactive tracer technique in detection of sentinel lymph node in breast cancer.
    Radovanovic Z; Golubovic A; Plzak A; Stojiljkovic B; Radovanovic D
    Eur J Surg Oncol; 2004 Nov; 30(9):913-7. PubMed ID: 15498633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repeat sentinel node biopsy should be considered in patients with locally recurrent breast cancer.
    Vugts G; Maaskant-Braat AJ; Voogd AC; van Riet YE; Luiten EJ; Rutgers EJ; Rutten HJ; Roumen RM; Nieuwenhuijzen GA
    Breast Cancer Res Treat; 2015 Oct; 153(3):549-56. PubMed ID: 26358709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Sentinel node biopsy for breast cancer patients at the Bács-Kiskun County Teaching Hospital].
    Cserni G; Rajtár M; Boross G; Sinkó M; Svébis M; Baltás B; Ambrózay E; Szúcs M
    Orv Hetil; 2002 Mar; 143(9):437-46. PubMed ID: 12013684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Omitting axillary lymph node dissection in sentinel node negative breast cancer patients is safe: a long term follow-up analysis.
    Torrenga H; Fabry H; van der Sijp JR; van Diest PJ; Pijpers R; Meijer S
    J Surg Oncol; 2004 Oct; 88(1):4-7; discussion 7-8. PubMed ID: 15384064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Axillary dissection is not required for all patients with breast cancer and positive sentinel nodes.
    Guenther JM; Hansen NM; DiFronzo LA; Giuliano AE; Collins JC; Grube BL; O'Connell TX
    Arch Surg; 2003 Jan; 138(1):52-6. PubMed ID: 12511150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sentinel node biopsy in breast cancer has a greater node positivity rate than axillary node sample: results from a retrospective analysis.
    Macaskill EJ; Dewar S; Purdie CA; Brauer K; Baker L; Brown DC
    Eur J Surg Oncol; 2012 Aug; 38(8):662-9. PubMed ID: 22592099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [lymphatic Mapping and Sentinel Lymph Node Biopsy in patients with Breast Cancer ].
    Gallegos-Hernández JF; Chávez-García MA; Nájera I; Ramírez-Ramírez L; Durán-Martínez M
    Gac Med Mex; 2003; 139(3):205-8. PubMed ID: 12872412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Exclusive use of blue dye to detect sentinel lymph nodes in breast cancer].
    Bühler H S; Rojas P H; Cayazzo M D; Cunill C E; Vesperinas A G; Hamilton S J
    Rev Med Chil; 2008 Aug; 136(8):1015-20. PubMed ID: 18949185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of sentinel node biopsy in breast cancer patients who receive a second radioisotope injection after visualization failure in lymphoscintigraphy.
    Meretoja TJ; Joensuu H; Heikkilä PS; Leidenius MH
    J Surg Oncol; 2010 Nov; 102(6):649-55. PubMed ID: 20976732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Processing sentinel nodes in breast cancer: when and how many?
    Schuman S; Walker G; Avisar E
    Arch Surg; 2011 Apr; 146(4):389-93. PubMed ID: 21502448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Staging and management of axillary lymph nodes in patients with local recurrence in the breast or chest wall after a previous negative sentinel node procedure.
    Derkx F; Maaskant-Braat AJ; van der Sangen MJ; Nieuwenhuijzen GA; van de Poll-Franse LV; Roumen RM; Voogd AC
    Eur J Surg Oncol; 2010 Jul; 36(7):646-51. PubMed ID: 20537838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Modulation of the axillary lymph node dissection in breast cancer].
    Procaccini E; Ruggiero R; Mansi L; Laprovitera AP; Rambaldi PF; Cuccurullo V; Ferrara A; Procaccini F; Zenone P
    Ann Ital Chir; 2003; 74(1):21-8; discussion 28-9. PubMed ID: 12870278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Localization of the sentinel lymph node in breast cancer by combined lymphoscintigraphy, blue dye and intraoperative gamma probe.
    Villa G; Gipponi M; Buffoni F; Vecchio C; Bianchi P; Agnese G; Di Somma C; Catturich A; Rosato F; Tomei D; Nicolò G; Badellino F; Mariani G; Canavese G
    Tumori; 2000; 86(4):297-9. PubMed ID: 11016707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Usefulness of lymphatic mapping with sub-areolar injection of patent blue dye, in the typification of breast cancer].
    Gallegos-Hernández JF; Chávez-García M
    Rev Invest Clin; 2003; 55(4):407-11. PubMed ID: 14635604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.